Hopewell Therapeutics Announces Sublicense of Proprietary Lipid Nanoparticles for Novel Cancer Vaccine to Foxcroft Therapeutics

AI Briefing

• – Hopewell Therapeutics grants Foxcroft Therapeutics a global sublicense for its proprietary lipid nanoparticles for a novel cancer vaccine.
• – The sublicense enables Foxcroft to evaluate Hopewell's tissue-targeting lipid nanoparticles as potential delivery vehicles for its cancer vaccines.
• – The companies will collaborate on the evaluation and development of the technology.